Sun Pharmaceutical Industries Limited has announced the appointment of Deloitte Haskins & Sells Chartered Accountants LLP as its new Statutory Auditors. This appointment follows the mandatory auditor rotation requirement and will be for a term of five consecutive years, commencing after the Annual General Meeting for the financial year 2026-27. The decision was approved by the Board of Directors, subject to shareholder approval.
Sun Pharma Appoints New Statutory Auditors
The Board of Directors of Sun Pharmaceutical Industries Limited has approved the appointment of Deloitte Haskins & Sells Chartered Accountants LLP as the company’s new Statutory Auditors. This decision comes as the current auditors, SRBC & CO LLP, complete their second consecutive five-year term at the conclusion of the Annual General Meeting (AGM) for the financial year 2026-27.
Mandatory Auditor Rotation
The change aligns with the mandatory auditor rotation requirements stipulated under Section 139(2) of the Companies Act, 2013. Deloitte Haskins & Sells Chartered Accountants LLP has been appointed for a term of five consecutive years. This term will commence from the conclusion of the company’s AGM for the financial year 2026-27 and will extend until the conclusion of the AGM for the financial year 2031-32. The appointment is subject to the subsequent approval of the shareholders.
Auditor Profile
Deloitte Haskins & Sells Chartered Accountants LLP is a firm registered with the Institute of Chartered Accountants of India (ICAI) and is part of the global Deloitte network. The firm possesses extensive experience in auditing large listed and multinational corporations across various sectors, with a notable specialization in pharmaceuticals, life sciences, and healthcare. Their multidisciplinary team of specialists offers comprehensive audit, tax, and technology services.
Board Meeting Details
The Board Meeting during which this appointment was approved commenced at 10:45 AM (IST) and concluded at 02:55 PM (IST), following a break. The disclosures pertaining to this appointment, as required by Regulation 30 of the Listing Regulations, have been enclosed as Annexure A.
Source: BSE
